These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31033218)

  • 1. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
    Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
    J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Fujiwara H; Kaku K
    J Diabetes Investig; 2019 Sep; 10(5):1272-1283. PubMed ID: 30702214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Senda M; Kakiuchi S; Kameda H; Tamura M; Kurihara Y; Gunji R; Fujii S; Kaku K
    J Diabetes Investig; 2020 Jan; 11(1):132-141. PubMed ID: 31197929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT).
    Utsunomiya K; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Koshida R; Kameda H; Tamura M; Kaku K
    J Diabetes Investig; 2020 Jul; 11(4):906-916. PubMed ID: 32034997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT).
    Utsunomiya K; Koshida R; Kakiuchi S; Senda M; Fujii S; Kurihara Y; Gunji R; Kaku K
    J Diabetes Investig; 2021 Feb; 12(2):184-199. PubMed ID: 32597517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52-week, open-label, single-arm study.
    Seino Y; Yabe D; Sasaki T; Fukatsu A; Imazeki H; Ochiai H; Sakai S
    J Diabetes Investig; 2018 Mar; 9(2):332-340. PubMed ID: 28502112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
    Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
    Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
    Tanizawa Y; Kaku K; Araki E; Tobe K; Terauchi Y; Utsunomiya K; Iwamoto Y; Watada H; Ohtsuka W; Watanabe D; Suganami H;
    Expert Opin Pharmacother; 2014 Apr; 15(6):749-66. PubMed ID: 24512053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study).
    Kaku K; Naito Y; Senda M; Kurihara Y; Gunji R; Kakiuchi S; Utsunomiya K
    J Diabetes Investig; 2020 Mar; 11(2):405-416. PubMed ID: 31390166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
    Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
    Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
    Tobe K; Suganami H; Kaku K
    J Diabetes Investig; 2018 Jul; 9(4):862-869. PubMed ID: 29032638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A post-marketing study (J-STEP/EL Study).
    Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Fujii S; Kakiuchi S; Fujiwara H; Kameda H; Tamura M; Kaku K
    J Diabetes Investig; 2017 Nov; 8(6):766-775. PubMed ID: 28107773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
    Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
    Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
    Utsunomiya K; Shimmoto N; Senda M; Kurihara Y; Gunji R; Kameda H; Tamura M; Mihara H; Kaku K
    J Diabetes Investig; 2016 Sep; 7(5):755-63. PubMed ID: 27181254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study.
    Harashima SI; Inagaki N; Kondo K; Maruyama N; Otsuka M; Kawaguchi Y; Watanabe Y
    Diabetes Obes Metab; 2018 Jul; 20(7):1770-1775. PubMed ID: 29473709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Durable Safety and Effectiveness of Lixisenatide in Japanese People with Type 2 Diabetes: The Post-Marketing Surveillance PRANDIAL Study.
    Terauchi Y; Usami M; Inoue T
    Adv Ther; 2022 Jun; 39(6):2873-2888. PubMed ID: 35449321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study.
    Nakaguchi H; Kondo Y; Kyohara M; Konishi H; Oiwa K; Terauchi Y
    J Diabetes Investig; 2020 Nov; 11(6):1542-1550. PubMed ID: 32279451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2021 Jan; 20(1):4. PubMed ID: 33397376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
    J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.